Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Belhaven Biopharma Inc. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 pending office actions are assigned to 4 distinct examiners, meaning each application is under the review of a different individual. The work is also distributed across 4 distinct art units, suggesting that each of the 4 pending office actions involves a different technical specialty within the Biotechnology & Pharmaceuticals field.
GRAY, PHILLIP A is the busiest examiner, though he handles 1 pending office action. Because there are 4 distinct examiners and 4 distinct art units for the current workload, there is no concentration of influence in the portfolio. Each of the 4 pending office actions must be managed as a standalone case with its own examiner and art unit guidelines. This structure requires the company to address four different sets of expectations in the Biotechnology & Pharmaceuticals sector, as no two applications share the same examining personnel. The 1 pending office action assigned to the busiest examiner reflects the decentralized nature of the company's current prosecution efforts across the 4 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRAY, PHILLIP A | 1 | 74.1% | +10.8% |
| WHEELER, THURMAN MICHAEL | 1 | 45.8% | +23.5% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19554182 | COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE | GRAY, PHILLIP A | — |
| 19243303 | COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE | WHEELER, THURMAN MICHAEL | — |
| 19242213 | COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE | LEE, SIN J | — |
| Art Unit | Apps |
|---|---|
| 3783 | 1 |
| 1619 | 1 |
| 1613 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19554182 | COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE | GRAY, PHILLIP A | 3783 | §102 | Final Rejection | — | Pending | Mar 02, 2026 |
| 19243303 | COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE | WHEELER, THURMAN MICHAEL | 1619 | §103§112DP | Non-Final OA | — | Pending | Jun 19, 2025 |
| 19242213 | COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE | LEE, SIN J | 1613 | §103DP | Non-Final OA | — | Pending | Jun 18, 2025 |
| 19242195 | COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE | MERCIER, MELISSA S | 1615 | Other | Final Rejection | — | Pending | Jun 18, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBelhaven Biopharma Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Phillip A Gray has the most, with 1 of Belhaven Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
